Loading
A phase 2 trial of Rocbrutinib in mantle cell lymphoma, run by Guangzhou Lupeng Pharmaceutical Company LTD., active and no longer recruiting.
A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma is a phase 2 interventional study registered as NCT05716087 by Guangzhou Lupeng Pharmaceutical Company LTD., with 62 participants planned, started 2023-02-21 and due to reach its primary completion in 2024-12-05. Interventions recorded: Rocbrutinib. Conditions listed: Mantle Cell Lymphoma (MCL). No results are recorded here; the registry entry is the source.
Shares Rocbrutinib, Lupeng Pharmaceuticals, Mantle cell lymphoma.
Shares Rocbrutinib, Lupeng Pharmaceuticals, Mantle cell lymphoma.
Shares Rocbrutinib, Lupeng Pharmaceuticals.